Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan Approves Dexamethasone as Coronavirus Treatment
Details : The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2020
Lead Product(s) : Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Limaprost Alfadex
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg to a formulation which has been improved for moisture resistance stability following the technology transfer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : Limaprost Alfadex
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?